Which meeting are you claiming credit for?
*
Friday October 24th 2025
Thursday October 23rd 2025
Monday October 20th 2025
September 22nd 2025
September 9th 2025
July 17th 2025
June 19th 2025
May 22nd 2025
April 16th 2025
March 5th 2025
September 30th 2024
September 27th 2024
September 17th 2024
August 22nd 2024
July 5th 2024
Full Name
*
Email
*
example@example.com
Institution
Degrees
1. The most commonly found antibody in myasthenia gravis is:
a. Antibody to muscle specific kinase protein
b. Antibody to lipoprotein receptor-related protein 4
c. Antibody to acetylcholine receptor protein
d. Antibody to titin protein
2. Pathogenic mechanisms of myasthenia gravis include all but:
a. Antibody blocking of acetylcholine binding to the receptor
b. Enhance internalization and degradation of the acetylcholine receptor
c. Antibody activation of the terminal complement cascade
d. Antibody blockade of the sodium channel
3. The neonatal Fc receptor is:
a. A salvage pathway for immunoglobulin G
b. A salvage pathway for immunoglobulin G and M
c. A receptor protein that inhibits antibody formation
d. A receptor protein that promotes complement activation
4. Efgartigimod is:
a. A monoclonal antibody targeting the neonatal Fc receptor
b. A monoclonal antibody that promotes degradation of albumin and IgG
c. A small IgG1 Fc fragment that binds to the neonatal Fc receptor
d. A small IgG1 Fc fragment that blocks the cytoplasmic lysosomes
5. The ADAPT phase 3 trial for myasthenia gravis demonstrated efficacy in response compare to placebo in:
a. MG-ADL score but not QMG score
b. Minimal Symptom Expression score only
c. QMG score but not MG-ADL score
d. MG-ADL and QMG scores
Submit
Should be Empty: